Role of the transforming-growth-factor-β1 gene in late-onset alzheimer's disease: Implications for the treatment

Current Genomics

Volumn 14, Issue 2, 2013, Pages 147-156

  Bosco, Paolo ^a   Ferri, Raffaele ^a   Salluzzo, Maria Grazia ^a   Castellano, Sabrina ^b   Signorelli, Maria ^b   Nicoletti, Ferdinando ^c,d   Di Nuovo, Santo ^b   Drago, Filippo ^b   Caraci, Filippo ^a,b  

^a OASI RESEARCH INSTITUTE IRCCS   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

Alzheimer's disease; Depression; Drugs; Genetic polymorphism; Risk factor; Transforming growth factor 1

Indexed keywords

APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; N METHYL DEXTRO ASPARTIC ACID; PAROXETINE; SERTRALINE; TRANSFORMING GROWTH FACTOR BETA1; VENLAFAXINE;

ALZHEIMER DISEASE; CELL DIFFERENTIATION; CELL GROWTH; DEPRESSION; EMBRYO DEVELOPMENT; GENE FREQUENCY; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR DEPRESSION; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84874835774     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/1389202911314020007     Document Type: Review

References (120)

1. Hardy, J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem., 2009, 110(4), 1129-1134.
2. Ballard, C.; Day, S.; Sharp, S.; Wing, G.; Sorensen, S. Neuropsychiatric symptoms in dementia: importance and treatment considerations. Int. Rev. Psychiatry, 2008, 20(4), 396-404.
3. Fang, Y.; Zhang, L.; Zeng, Z.; Lian, Y.; Jia, Y.; Zhu, H.; Xu, Y. Promoter polymorphisms of serpine1 are associated with the antidepressant response to depression in Alzheimer's disease. Neurosci. Lett., 2012, 516(2), 217-220.
4. Combarros, O.; Alvarez-Arcaya, A.; Oterino, A.; Berciano, J.; Delgado-Rodríguez, M.; Peña N.; Fernández-Viadero, C.; Pérez- López, L.J.; Setién, S.; Carvajal, A. Polymorphisms in the presenilin 1 and presenilin 2 genes and risk for sporadic alzheimer's disease. J. Neurol. Sci., 1999, 171(2), 88-91.
5. Di Fede, G.; Catania, M.; Morbin, M.; Rossi, G.; Suardi, S.; Mazzoleni, G.; Merlin, M.; Giovagnoli, A.R.; Prioni, S.; Erbetta, A.; Falcone, C.M.; Gobbi, M.; Colombo, L.; Bastone, A.; Beeg, M.; Manzoni, C.; Francescucci, B.; Spagnoli, A.; Cantù, L.; Del Favero, E.; Levy, E.; Salmona, M.; Tagliavini, F. A recessive mutation in the APP gene with dominant- negative effect on amyloidogenesis. Science, 2009, 323(5920), 1473-1477.
6. Bertram, L.; Lill, C.M.; Tanzi, R.E. The genetics of Alzheimer disease: back to the future. Neuron., 2010, 68(2), 270-281.
7. Lacor, P.N. Advances on the Understanding of the Origins of Synaptic Pathology in AD. Curr. Genomics, 2007, 8(8), 486-508.
8. St Clair, D.; Rennie, M.; Slorach, E.; Norrman, J.; Yates, C.; Carothers, A. Apolipoprotein E 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers. J Med Genet., 1995, 32(8), 642-644.
9. Dal Forno, G.; Rasmusson, D. X.; Brandt, J.; Carson, K. A.; Brookmeyer, R.; Troncoso, J.; Kawas, C.H. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch. Neurol., 1996, 53(4), 345-350.
10. Bosco, P.; Guéant-Rodríguez, RM.; Anello, G.; Spada, RS.; Romano, A.; Caraci, F.; Ferri, R.; Guéant, JL. Allele epsilon 4 of APOE is a stronger predictor of Alzheimer risk in sicily than in continental south Italy. Neurosci. Lett., 2005, 18388(3), 168-172.
11. Brousseau, T.; Legrain, S.; Berr, C.; Gourlet, V.; Vidal, O.; Amouyel, P. Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology, 1994, 44(2), 342-344.
12. Corder, E.H.; Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C.; Small, G.W. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993, 261(5123), 921-923.
13. Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.; George-Hyslop, P.H.; Pericak-Vance, M.A.; Joo, S.H. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology, 1993, 43(8),1467-1472.
14. Strittmatter WJ.; Saunders, AM.; Schmechel, D.; Pericak-Vance, M.; Enghild, J.; Salvesen, GS. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in lateonset familial Alzheimer disease. Proc. Natl. Acad Sci. U S A. 1993, 90(5), 1977-1981.
15. Genin, E.; Hannequin, D.; Wallon, D.; Sleegers, K.; Hiltunen, M.; Combarros, O.; Bullido, M.J.; Engelborghs, S.; De Deyn, P.; Berr, C.; Pasquier, F.; Dubois, B.; Tognoni, G.; Fiévet, N.; Brouwers, N.; Bettens, K.; Arosio, B.; Coto, E.; Del Zompo, M.; Mateo, I.; Epelbaum, J.; Frank-Garcia, A.; Helisalmi, S.; Porcellini, E.; Pilotto, A.; Forti, P.; Ferri, R.; Scarpini, E.; Siciliano, G.; Solfrizzi, V.; Sorbi, S.; Spalletta, G.; Valdivieso, F.; Vepsäläinen, S.; Alvarez, V.; Bosco, P.; Mancuso, M.; Panza, F.; Nacmias, B.; Bossù, P.; Hanon, O.; Piccardi, P.; Annoni, G.; Seripa, D.; Galimberti, D.; Licastro, F.; Soininen, H.; Dartigues, J.F.; Kamboh, M.I.; Van Broeckhoven, C.; Lambert, J.C.; Amouyel, P.; Campion, D. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol. Psychiatry. 2011, 16(9), 903-907.
16. Wu, P.; Hu, Y. Definition of Genes and Paths Involved in Alzheimer's Disease: Using Gene Expression Profiles and Chemical Genetics at the Mouse Brain Level. Curr. Genomics, 2006, 7(5), 293-300.
17. Griffin, W.S.; Mrak, R.E. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J. Leukoc. Biol., 2002, 72(2), 233-238.
18. Grimaldi, L.M.; Casadei, V.M.; Ferri, C.; Veglia, F.; Licastro, F.; Annoni, G.; Biunno, I.; De Bellis, G.; Sorbi, S.; Mariani, C.; Canal, N.; Griffin, W.S.; Franceschi, M. Association of early-onset Alzheimer's disease with an interleukin-1 alpha gene polymorphism. Ann. Neurol., 2000, 47(3), 361-365.
19. Nishiyama, M.; Kato, Y.; Hashimoto, M.; Yukawa, S.; Omori, K. Apolipoprotein E, Methylenetetrahydrofolate Reductase (MTHFR) mutation and the risk of senile dementia - an epidemiological study using the polymerase chain reaction (PCR). Method. Epidemiol., 2000, 10(3), 163-172
20. Coppedè, F. One-Carbon Metabolism and Alzheimer's Disease: Focus on Epigenetics. Curr. Genomics, 2010,11(4), 246-260.
21. Lambert J.C.; Amouyel P. Genetics of Alzheimer's disease: new evidences for an old hypothesis? Curr. Opin. Genet. Dev., 2011, 21(3), 295-301.
22. Lambert, J.C.; Heath, S.; Even, G.; Campion, D.; Sleegers, K.; Hiltunen, M.; Combarros, O.; Zelenika, D.; Bullido, M.J.; Tavernier, B.; Letenneur, L.; Bettens, K.; Berr, C.; Pasquier, F.; Fiévet, N.; Barberger-Gateau, P.; Engelborghs, S.; De Deyn, P.; Mateo, I.; Franck, A.; Helisalmi, S.; Porcellini, E.; Hanon, O. European Alzheimer's Disease Initiative Investigators, de Pancorbo, M.M.; Lendon, C.; Dufouil, C.; Jaillard, C.; Leveillard, T.; Alvarez, V.; Bosco, P.; Mancuso, M.; Panza, F.; Nacmias, B.; Bossù, P.; Piccardi, P.; Annoni, G.; Seripa, D.; Galimberti, D.; Hannequin, D.; Licastro, F.; Soininen, H.; Ritchie, K.; Blanché, H.; Dartigues, J.F.; Tzourio, C.; Gut, I.; Van Broeckhoven, C.; Alpérovitch, A.; Lathrop, M.; Amouyel, P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet., 2009, 41(10), 1094-1099.
23. Hollingworth, P.; Harold, D.; Sims, R.; Gerrish, A.; Lambert, J.C.; Carrasquillo, M.M.; Abraham, R.; Hamshere, M.L.; Pahwa, J.S.; Moskvina, V.; Dowzell, K.; Jones, N.; Stretton, A.; Thomas, C.; Richards, A.; Ivanov, D.; Widdowson, C.; Chapman, J.; Lovestone, S.; Powell, J.; Proitsi, P.; Lupton, M.K.; Brayne, C.; Rubinsztein, D.C.; Gill, M.; Lawlor, B.; Lynch, A.; Brown, K.S.; Passmore, P.A.; Craig, D.; McGuinness, B.; Todd, S.; Holmes, C.; Mann, D.; Smith, A.D.; Beaumont, H.; Warden, D.; Wilcock, G.; Love, S.; Kehoe, P.G.; Hooper, N.M.; Vardy, E.R.; Hardy, J.; Mead, S.; Fox, N.C.; Rossor, M.; Collinge, J.; Maier, W.; Jessen, F.; Rüther, E.; Schürmann, B.; Heun, R.; Kölsch, H.; van den Bussche, H.; Heuser, I.; Kornhuber, J.; Wiltfang, J.; Dichgans, M.; Frölich, L.; Hampel, H.; Gallacher, J.; Hüll, M.; Rujescu, D.; Giegling, I.; Goate, A.M.; Kauwe, J.S.; Cruchaga, C.; Nowotny, P.; Morris, J.C.; Mayo, K.; Sleegers, K.; Bettens, K.; Engelborghs, S.; De Deyn, P.P.; Van Broeckhoven, C.; Livingston, G.; Bass, N.J.; Gurling, H.; McQuillin, A.; Gwilliam, R.; Deloukas, P.; Al- Chalabi, A.; Shaw, C.E.; Tsolaki, M.; Singleton, A.B.; Guerreiro, R.; Mühleisen, T.W.; Nöthen, M.M.; Moebus, S.; Jöckel, K.H.; Klopp, N.; Wichmann, H.E.; Pankratz, V.S.; Sando, S.B.; Aasly, J.O.; Barcikowska, M.; Wszolek, Z.K.; Dickson, D.W.; Graff- Radford, N.R.; Petersen, R.C. Alzheimer's Disease Neuroimaging Initiative, van Duijn, C.M.; Breteler, M.M.; Ikram, M.A.; DeStefano, A.L.; Fitzpatrick, A.L.; Lopez, O.; Launer, L.J.; Seshadri, S. CHARGE consortium, Berr, C.; Campion, D.; Epelbaum, J.; Dartigues, J.F.; Tzourio, C.; Alpérovitch, A.; Lathrop, M. EADI1 consortium, Feulner, T.M.; Friedrich, P.; Riehle, C.; Krawczak, M.; Schreiber, S.; Mayhaus, M.; Nicolhaus, S.; Wagenpfeil, S.; Steinberg, S.; Stefansson, H.; Stefansson, K.; Snaedal, J.; Björnsson, S.; Jonsson, P.V.; Chouraki, V.; Genier-Boley, B.; Hiltunen, M.; Soininen, H.; Combarros, O.; Zelenika, D.; Delepine, M.; Bullido, M.J.; Pasquier, F.; Mateo, I.; Frank-Garcia, A.; Porcellini, E.; Hanon, O.; Coto, E.; Alvarez, V.; Bosco, P.; Siciliano, G.; Mancuso, M.; Panza, F.; Solfrizzi, V.; Nacmias, B.; Sorbi, S.; Bossù, P.; Piccardi, P.; Arosio, B.; Annoni, G.; Seripa, D.; Pilotto, A.; Scarpini, E.; Galimberti, D.; Brice, A.; Hannequin, D.; Licastro, F.; Jones, L.; Holmans, P.A.; Jonsson, T.; Riemenschneider, M.; Morgan, K.; Younkin, S.G.; Owen, M.J.; O'Donovan, M.; Amouyel, P.; Williams, J. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet., 2011, 43(5), 429-435.
24. Cotman, C.W. The role of neurotrophins in brain aging: a perspective in honor of Regino Perez-Polo. Neurochem. Res., 2005, 30(6- 7), 877-881.
25. Borroni, B.; Archetti, S.; Costanzi, C.; Grassi, M.; Ferrari, M.; Radeghieri, A; Caimi, L.; Caltagirone, C.; Di Luca M.; Padovani, A.ITIN Alzheimer's disease Working Group. Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression Neurobiol. Aging, 2009, 30(9), 1406-1412.
26. Caraci, F.; Battaglia, G.; Bruno, V.; Bosco, P.; Carbonaro, V.; Giuffrida, M.L.; Drago, F.; Sortino, M.A.; Nicoletti, F.; Copani, A. TGF-β1 Pathway as a new target for neuroprotection in alzheimer's disease. CNS Neurosci. Ther., 2011, 17(4), 237-249.
27. Ten Dijke, P.; Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem. Sci., 2004, 29(5), 265-273.
28. Li, M.O.; Wan, Y.Y.; Sanjabi, S.; Robertson, A.K.; Flavell, R.A. Transforming growth factor- β regulation of immune responses. Annu. Rev. Immunol., 2006, 24, 99-146.
29. Hamaguchi, T.; Okino, S.; Sodeyama, N.; Itoh, Y.; Takahashi, A.; Otomo, E.; Matsushita, M.; Mizusawa, H.; Yamada, M. Association of a polymorphism of the transforming growth factor-b1 gene with cerebral amyloid angiopathy. J. Neurol. Neurosurg. Psychiatry, 2005, 76(5), 696-699.
30. Caraci, F.; Spampinato, S.; Sortino, M.A.; Bosco, P.; Battaglia, G.; Bruno, V.; Drago, F.; Nicoletti, F.; Copani, A. Dysfunction of TGF-β1 signaling in Alzheimer's disease: perspectives for neuroprotection. Cell. Tissue Res., 2012, 347(1), 291-301.
31. Taipale, J.; Saharinen, J.; Keski-Oja, J. Extracellular matrixaassociated transforming growth factor-beta: role in cancer cell growth and invasion. Adv. Cancer Res.,1998, 75, 87-134.
32. Grainger, D.J.; Heathcote, K.; Chiano, M.; Snieder, H.; Kemp, P.R.; Metcalfe, J.C.; Carter, N.D.; Spector, T.D. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum. Mol. Genet., 1999, 8(1), 93-97.
33. Syrris, P.; Carter, N.D.; Metcalfe, J.C.; Kemp, P.R.; Grainger, D.J.; Kaski, J.C.; Crossman, D.C.; Francis, S.E.; Gunn, J.; Jeffery, S.; Heathcote, K. Transforming growth factor-b1 gene polymorphisms and coronary artery disease. Clinical Science, 1998, 95(6), 659-667.
34. Awad, M.R.; El-Gamel, A.; Hasleton, P.; Turner, D.M.; Sinnott, P.J.; Hutchinson I.V. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation, 1998, 66(8), 1014-1020.
35. Derynck, R.; Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 2203, 425(6958), 577-84.
36. König, H.G.; Kögel, D.; Rami, A.; Prehn, J.H. TGF-{beta}1 activates two distinct type I receptors in neurons: implications for neuronal NF-{kappa}B signaling. J. Cell. Biol., 2005, 168(7), 1077-86.
37. Bakin, A.V.; Tomlinson, A.K.; Bhowmick, N.A.; Moses, H.L. & Arteaga C.L. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem., 2000, 275(47), 36803-36810.
38. Caraci, F.; Battaglia, G.; Busceti, C.; Biagioni, F.; Mastroiacovo, F.; Bosco, P.; Drago, F.; Nicoletti, F.; Sortino, M.A.; Copani, A. TGF-beta 1 protects against Abeta-neurotoxicity via the phosphatidylinositol- 3-kinase pathway. Neurobiol. Dis., 2008, 30(2), 234-242.
39. Zhu, Y.; Culmsee, C.; Klumpp, S.; Krieglstein, J. Neuroprotection by transforming growth factor-beta1 involves activation of nuclear factor-kappaB through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein kinase-extracellular-signal regulated kinase1,2 signaling pathways. Neuroscience, 2004, 123(4), 897-906.
40. Kim, S.J.; Denhez, F.; Kim, K.Y.; Holt, J.T.; Sporn, M.B.; Roberts, A.B. Activation of the second promoter of the transforming growth factor-beta 1 gene by transforming growth factor-beta 1 and phorbol ester occurs through the same target sequences. J. Biol. Chem., 1989, 264(32), 19373-19378.
41. Kim, S.J.; Glick, A.; Sporn, M.B.; Roberts, A.B. Characterization of the promoter region of the human transforming growth factorbeta 1 gene. J. Biol. Chem., 1989, 264(1), 402-408.
42. Cambien, F.; Ricard, S.; Troesch, A.; Mallet, C.; Générénaz, L.; Evans, A.; Arveiler, D.; Luc, G.; Ruidavets, J.B.; Poirier, O. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas- Témoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension, 1996, 28(5), 881-887.
43. Araria-Goumidi, L.; Lambert, J.C.; Mann, D.M.; Lendon, C.; Frigard, B.; Iwatsubo, T.; Cottel, D.; Amouyel, P.; Chartier-Harlin, M.C. Association study of three polymorphisms of TGF-beta1 gene with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 2002, 73(1), 62-64.
44. Tzakas, P.; Wong, B.Y.; Logan, A.G.; Rubin, L.A.; Cole, D.E.; Transforming growth factor beta-1 (TGFB1) and peak bone mass: association between intragenic polymorphisms and quantitative ultrasound of the heel. BMC Musculoskelet. Disord., 2005, 6,
45. Lario, S.; Iñigo, P.; Campistol, J.M.; Poch, E.; Rivera, F.; Oppenheimer, F. Restriction enzyme-based method for transforming growth factor-beta (1) genotyping: nonisotopic detection of polymorphisms in codons 10 and 25 and the 5'-flanking region. Clin. Chem., 1999, 45(8), 1290-1292.
46. Bidwell, J.; Keen, L.; Gallagher, G.; Kimberly, R.; Huizinga, T.; McDermott, M.F.; Oksenberg, J.; McNicholl, J.; Pociot, F.; Hardt, C.; D'Alfonso, S. Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun., 2001, 2(2), 61-70.
47. Li, B.; Khanna, A.; Sharma, V.; Singh, T.; Suthanthiran, M.; August, P. TGF-beta1 DNA polymorphisms, levels, and blood pressure. Hypertension, 1999, 33(1), 271-275.
48. Suthanthiran, M.; Li, B.; Song, J.O.; Ding, R.; Sharma, V.K.; Schwartz, J.E.; August, P. Transforming growth factor-beta 1 hyperexpression in african-american hypertensives: a novel mediator of hypertension and/or target organ damage. Proc. Natl. Acad. Sci. U S A, 2000, 97(7), 3479-3484.
49. Wood, N.A.; Thomson, S.C.; Smith, R.M.; Bidwell, J.L. Identification of human TGF-beta1 signal (leader) sequence polymorphisms by PCR-RFLP. J. Immunol. Methods, 2000, 234(1-2), 117-122.
50. Samani, N.J. Molecular genetics of coronary artery disease: measuring the phenotype. Clin. Sci. (Lond)., 1998, 95(6), 645-646.
51. Cardillo, MR.; Yap, E.; Castagna, G. Molecular genetic analysis of TGF beta1 in breast cancer. J. Exp. Clin. Cancer Res., 1997, 16(1), 57-63.
52. Cardillo, M.R.; Yap, E. TGF-beta1 in colonic neoplasia: a genetic molecular and immunohistochemical study. J. Exp. Clin. Cancer Res., 1997, 16(3), 281-288.
53. Cardillo, M.R.; Yap, E.; Castagna, G. Molecular genetic analysis of TGF-beta1 in ovarian neoplasia. J. Exp. Clin. Cancer Res., 1997, 16(1), 49-56.
54. Matsuzaki, K. Modulation of TGF-beta signaling during progression of chronic liver diseases. Front Biosci., 2009, 14, 2923-34.
55. Lee, J.J., Park, S.K., Kwon, O.S., Won, I.S., Kim, D.K., Jung, Y.K., Ku, Y.S., Kim, Y.S., Choi, D.J., Kim, J.H. Genetic polymorphism at codon 10 of the transforming growth factor-β1 gene in patients with alcoholic liver cirrhosis. Korean J Hepatol., 2011, 17(1), 37-43.
56. Arias, M., Lahme, B., Van de Leur, E., Gressner, A.M., Weiskirchen, R. Adenoviral delivery of an antisense RNA complementary to the 3' coding sequence of transforming growth factor- beta1 inhibits fibrogenic activities of hepatic stellate cells. Cell Growth Differ., 2002, 13(6), 265-73.
57. Osterreicher CH, Halangk J, Berg T, Patsenker E, Homann N, Hellerbrand C, Seitz HK, Eurich D, Stickel F. Evaluation of the transforming growth factor beta1 codon 25 (Arg-->Pro) polymorphism in alcoholic liver disease. Cytokine, 2008, 42(1), 18-23
58. Pociot, F.; Hansen, P.M.; Karlsen, A.E.; Langdahl, B.L.; Johannesen, J.; Nerup, J. TGF-beta1 gene mutations in insulindependent diabetes mellitus and diabetic nephropathy. J. Am. Soc. Nephrol., 1998, 9(12), 2302-2307.
59. Hobbs, K.; Negri, J.; Klinnert, M.; Rosenwasser, L.J.; Borish, L. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. Am. J. Respir. Crit. Care Med., 1998, 158(6), 1958-1962.
60. He, B.; Xu, C.; Landtblom, A.M.; Fredrikson, S.; Hillert, J. Linkage and association analysis of genes encoding cytokines and myelin proteins in multiple sclerosis. J. Neuroimmunol., 1998, 86(1), 13-19.
61. Sugiura, Y.; Niimi, T.; Sato, S.; Yoshinouchi, T.; Banno, S.; Naniwa, T.; Maeda, H.; Shimizu, S.; Ueda, R. Transforming growth factor beta1 gene polymorphism in rheumatoid arthritis. Ann. Rheum. Dis., 2002, 61(9) 826-828.
62. Yamada, Y.; Miyauchi, A.; Goto, J.; Takagi, Y.; Okuizumi, H.; Kanematsu, M.; Hase, M.; Takai, H.; Harada, A.; Ikeda, K. Asso ciation of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J. Bone Miner. Res., 1998, 13(10), 1569-1576.
63. Langdahl, B.L.; Knudsen, J.Y.; Jensen, H.K.; Gregersen, N.; Eriksen, E.F. A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone, 1997, 20(3), 289-294.
64. Finch, C.E.; Laping, N.J.; Morgan, T.E.; Nichols, N.R.; Pasinetti, G.M. TGF-β1 is an organizer of response to neurodegeneration. J. Cell. Biochem., 1993, 53(4), 314-322.
65. Salvioli, S.; Capri, M.; Bucci, L. Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53. Cancer Immunol. Immunother., 2009, 58(12), 1909-1917.
66. Carrieri, G.; Marzi, E.; Olivieri, F. The G/C 915 polymorphism of transforming growth factor beta1 is associated with human longevity: a study in Italian centenarians. Aging Cell., 2004, 3(6), 443-448.
67. Forsey, R.J.; Thompson, J.M.; Ernerudh, J. Plasma cytokine profiles in elderly humans. Mech. Ageing Dev., 2003, 124(4), 487-493.
68. Tesseur, I.; Zou, K.; Esposito, L.; Bard, F.; Berber, E.; Can, J.V.; Lin, A.H.; Crews, L.; Tremblay, P.; Mathews, P.; Mucke, L.; Masliah, E.; Wyss-Coray, T. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J. Clin. Invest., 2006, 116(11), 3060-3069.
69. Mocali, A.; Cedrola, S.; Della Malva, N.; Bontempelli, M.; Mitidieri, V.A.; Bavazzano, A.; Comolli, R.; Paoletti, F.; La Porta, C.A. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Exp. Gerontol., 2004, 39(10), 1555-1561.
70. Juraskova, B.; Andrys, C.; Holmerova, I.; Solichova, D.; Hrnciarikova, D.; Vankova, H.; Vasatko, T.; Krejsek, J. Transforming growth factor Beta and soluble endoglin in the healthy senior and in Alzheimer 's disease patients. J. Nutr. Health Aging, 2010, 14(9), 758-761.
71. Luppi, C.; Fioravanti, M.; Bertolini, B.; Inguscio, M.; Grugnetti, A.; Guerriero, F.; Rovelli, C.; Cantoni, F.; Guagnano, P.; Marazzi, E.; Rolfo, E.; Ghianda, D.; Levante, D.; Guerrini, C.; Bonacasa, R.; Solerte, S.B. Growth factors decrease in subjects with mild to moderate Alzheimer's disease (AD): potential correction with dehydroepiandrosterone- sulphate (DHEAS). Arch. Gerontol. Geriatr., 2009, 49, 173-184.
72. Wyss-Coray, T. Tgf-Beta pathway as a potential target in neurodegeneration and Alzheimer's. Curr. Alzh. Res., 2006, 3(3), 191-195.
73. Lahiri, D.K.; Ge, Y.W.; Role of the APP promoter in Alzheimer's disease: cell type-specific expression of the beta-amyloid precursor protein. Ann. N. Y. Acad Sci., 2004, 1030, 310-316.
74. Luedecking, E.K.; DeKosky, S.T.; Mehdi, H.; Ganguli, M.; Kamboh, M.I. Analysis of genetic polymorphisms in the transforming growth factor-beta1 gene and the risk of Alzheimer's disease. Hum. Genet., 2000, 106(5), 565-569.
75. Burton, T.; Liang, B.; Dibrov, A.; Amara, F. Transforming growth factor-beta-induced transcription of the Alzheimer beta-amyloid precursor protein gene involves interaction between the CTCF complex and Smads. Biochem. Biophys. Res. Commun., 2002, 295(3), 713-723.
76. Lesne, S.; Docagne, F.; Gabriel, C. Transforming growth factorbeta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J. Biol. Chem., 2003, 278(20), 18408-18418.
77. Hynd, M.R.; Scott, H.L.; Dodd. P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem. Int., 2004, 45(5), 583-595.
78. Caricasole, A.; Copani, A.; Caraci, F.; Aronica, E.; Rozemuller, A.J.; Caruso, A.; Storto, M.; Gaviraghi, G.; Terstappen, G.C.; Nicoletti, F. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J. Neurosci., 2004, 24(26), 6021-6027.
79. Herrup, K.; Neve, R.; Ackerman, S.L.; Copani, A. Divide and die: cell cycle events as triggers of nerve cell death. J. Neurosci., 2004, 24(42), 9232-9239.
80. Rojo, L.E.; Fernández, J.A.; Maccioni, A.A.; Jimenez, J.M.; Maccioni, R.B. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch. Med. Res., 2008, 39(1), 1-16.
81. Huang, W.C.; Yen, F.C.; Shie, F.S.; Pan, C.M.; Shiao, Y.J.; Yang, C.N.; Huang, F.L.; Sung, Y.J.; Tsay, H.J. TGF-beta1 blockade of microglial chemotaxis toward Abeta aggregates involves SMAD signaling and down-regulation of CCL5. J Neuroinflammation, 2010, 7(28), doi: 10.1186/1742-2094-7-28.
82. Dickson, M.R.; Perry, R.T.; Wiener, H.; Go, R.C. Association studies of transforming growth factor-beta 1 and Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2005, 139B(1), 38-41.
83. van Oijen, M.; Arp, P.P.; de Jong, F.J.; Hofman, A.; Koudstaal, P.J.; Uitterlinden, A.G.; Breteler, M.M. Polymorphisms in the interleukin 6 and transforming growth factor beta1 gene and risk of dementia. The Rotterdam Study. Neurosci. Lett., 2006, 402(1-2), 113-117.
84. Shawkatová, I.; Javor, J.; Párnická, Z.; Vražda, L.; Novák, M.; Buc, M. No association between cytokine gene polymorphism and risk of Alzheimeŕs disease in Slovaks. Acta Neurobiol. Exp., 2010, 70(3), 303-307.
85. Rodríguez-Rodríguez, E.; Sánchez-Juan, P.; Mateo, I.; Llorca, J.; Infante, J.; García-Gorostiaga, I.; Berciano, J.; Combarros, O. Serum levels and genetic variation of TGF-beta1 are not associated with Alzheimer's disease. Acta Neurol. Scand., 2007, 116(6), 409-412.
86. Peila, R.; Yucesoy, B.; White, L.R.; Johnson, V.; Kashon, M.L.; Wu, K.; Petrovitch, H.; Luster, M.; Launer, L.J. A TGF-beta1 polymorphism association with dementia and neuropathologies: the HAAS. Neurobiol. Aging, 2007, 28(9), 1367-1373.
87. Ribizzi, G.; Fiordoro, S.; Barocci, S.; Ferrari, E.; Megna, M. Cytokine polymorphisms and Alzheimer disease: possible associations. Neurol. Sci., 2010, 31(3), 321-325.
88. Arosio, B.; Bergamaschini, L.; Galimberti, L.; La Porta, C.; Zanetti, M.; Calabresi, C.; Scarpini, E.; Annoni, G.; Vergani, C. +10 T/C polymorphisms in the gene of transforming growth factorbeta1 are associated with neurodegeneration and its clinical evolution. Mech. Ageing Dev., 2007, 128(10), 553-557.
89. Caraci, F.; Bosco, P.; Signorelli, M.; Spada, R.S.; Cosentino, F.I.; Toscano, G.; Bonforte, C.; Muratore, S.; Prestianni, G.; Panerai, S.; Giambirtone, M.C.; Gulotta, E., Romano, C.; Salluzzo, M.G.; Nicoletti, F.; Copani, A.; Drago, F.; Aguglia, E.; Ferri R. The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression. Eur. Neuropsychopharmacol., 2012, 22(4), 281-289.
90. Adler, U.C.; Marques, A.H.; Calil, H.M. Inflammatory aspects of depression. Inflamm. Allergy Drug Targets, 2006, 7(1), 19-23.
91. Caraci, F.; Copani, A.; Nicoletti, F.; Drago, F. Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur. J. Pharmacol., 2010, 626(1), 64-71.
92. Starkstein, S.E.; Jorge, R.; Mizrahi, R.; Robinson, R.G. The construct of minor and major depression in Alzheimer's disease. Am. J. Psych., 2005, 162(11), 2086-2093.
93. Shim, Y.S.; Yang, D.W. Depression as prognostic factor: 6 months follow-up in a geriatric institution. Arch. Gerontol. Geriatr., 2006, 43(2), 277-283.
94. Ownby, R.L.; Crocco, E.; Acevedo, A.; John, V.; Loewenstein, D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch. Gen. Psychiatry, 2006, 63(5), 530-538.
95. Modrego, P.J.; Ferrández, J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch. Neurol., 2004, 61(3), 1290-1293.
96. Forlenza, O.V.; Diniz, B.S.; Teixeira, A.L.; Ojopi, E.B.; Talib, L.L.; Mendonça, V.A.; Izzo, G.; Gattaz, W.F. Effect of brainderived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J. Biol. Psychiatry, 2010, 11(6), 774-780.
97. McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R.; Kawas C.H, Jr.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; Mohs, R.C.; Morris, J.C.; Rossor, M.N.; Scheltens, P.; Carrillo, M.C.; Thies, B.; Weintraub, S.; Phelps, C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement., 2011, 7(3), 263-269.
98. Albert, M.S.; DeKosky, S.T.; Dickson, D.; Dubois, B.; Feldman, H.H.; Fox, N.C.; Gamst, A.; Holtzman, D.M.; Jagust, W.J.; Petersen, R.C.; Snyder, P.J.; Carrillo, M.C.; Thies, B.; Phelps, C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement., 2011, 7(3), 270-279.
99. Sperling, R.A.; Aisen, P.S.; Beckett, L.A.; Bennett, D.A.; Craft, S.; Fagan, A.M.; Iwatsubo, T.; Jack, C.R.; Jr. Kaye, J.; Montine, T.J.; Park, D.C.; Reiman, E.M.; Rowe, C.C.; Siemers, E.; Stern, Y.; Yaffe, K.; Carrillo, M.C.; Thies, B.; Morrison-Bogorad, M.; Wagster, M.V.; Phelps, C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement., 2011, 7(3), 280-292.
100. Cummings, J.L. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement., 2011, 7(3), e13-44.
101. Drago, V.; Babiloni, C.; Bartrés-Faz, D.; Caroli, A.; Bosch, B.; Hensch, T.; Didic, M.; Klafki, H.W.; Pievani, M.; Jovicich, J.; Venturi, L.; Spitzer, P.; Vecchio, F.; Schoenknecht, P.; Wiltfang, J.; Redolfi, A.; Forloni, G.; Blin, O.; Irving, E., Davis, C.; Hårdemark, H.G.; Frisoni, G.B. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. J. Alzheimers Dis., 2011, 26 suppl3, 159-199.
102. Zemva, J.; Schubert, M. Central insulin and insulin-like growth factor-1 signaling: implications for diabetes associated dementia. Curr. Diabetes Rev., 2011, 7(5), 356-366.
103. Zhuo, J.M.; Wang, H.; Praticò, D. Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol. Sci., 2011, 32(9), 562-571.
104. Coon, K.D.; Myers, A.J.; Craig, D.W.; Webster, J.A.; Pearson, J.V.; Lince, D.H.; Zismann, V.L.; Beach, T.G.; Leung, D.; Bryden, L.; Halperin, R.F.; Marlowe, L.; Kaleem, M.; Walker, D.G.; Ravid, R.; Heward, C.B.; Rogers, J.; Papassotiropoulos, A.; Reiman, E.M.; Hardy, J.; Stephan, D.A. A high-density whole genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J. Clin. Psychiatry, 2007, 68(4), 613-618.
105. Di Maria, E.; Giorgio, E.; Uliana, V.; Bonvicini, C.; Faravelli, F.; Cammarata, S.; Novello, M.C.; Galimberti, D.; Scarpini, E.; Zanetti, O.; Gennarelli, M.; Tabaton, M. Possible influence of a non-synonymous polymorphism located in the NGF precursor on susceptibility to late-onset Alzheimer's disease and mild cognitive impairment. J. Alzheimers Dis., 2012, 29(3), 699-705.
106. Wada, A.; Yokoo, H.; Yanagita, T.; Kobayashi, H. Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J. Pharmacol. Sci., 2005, 99(4), 307-321.
107. Lauterbach, E.C.; Victoroff, J.; Coburn, K.L.; Shillcutt, S.D.; Doonan, S.M.; Mendez, M.F. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J. Neuropsychiatry Clin. Neurosci., 2010, 22(1), 8-18.
108. Nunes, P.V.; Forlenza, O.V.; Gattaz, W.F. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br. J. Psychiatry, 2008, 190, 359-360.
109. Yeh, H.L.; Tsai, S.J. Lithium may be useful in the prevention of Alzheimer's disease in individuals at risk of presenile familial Alzheimer's disease. Med. Hypotheses, 2008, 71(6), 948-951.
110. Forlenza, O.V.; Diniz, B.S.; Radanovic, M.; Santos, F.S.; Talib, L.L.; Gattaz, W.F. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br. J. Psychiatry, 2011, 198(5), 351-356.
111. Caraci, F.; Molinaro, G.; Battaglia, G.; Giuffrida, M.L.; Riozzi, B.; Traficante, A.; Bruno, V.; Cannella, M.; Merlo, S.; Wang, X.; Heinz, B.A.; Nisenbaum, E.S.; Britton, T.C.; Drago, F.; Sortino, M.A.; Copani, A.; Nicoletti, F. Targeting group-II metabotropic glutamate receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies {beta}-amyloid toxicity in cultured neurons whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol. Pharmacol., 2011, 79(3), 618-626.
112. Patil, S.T.; Zhang, L.; Martenyi, F.; Lowe, S.L.; Jackson, K.A.; Andreev, B.V.; Avedisova, A.S.; Bardenstein, L.M.; Gurovich, I.Y.; Morozova, M.A.; Mosolov, S.N.; Neznanov, N.G.; Reznik, A.M.; Smulevich, A.B.; Tochilov, V.A.; Johnson, B.G.; Monn, J.A.; Schoepp, D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med., 2007,13(9), 1102-1107.
113. Kinon, B.J.; Zhang, L.; Millen, B.A.; Osuntokun, O.O.; Williams, J.E.; Kollack-Walker, S.; Jackson, K.; Kryzhanovskaya, L.; Jarkova, N.; and the HBBI Study Group. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J. Clin. Psychopharmacol., 2011, 31(3), 349-355.
114. Hwang, T.J.; Masterman, D.L.; Ortiz, F.; Fairbanks, L.A.; Cummings, J.L. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis. Assoc. Disord., 2004, 18(1),17-21.
115. Sutcigil, L.; Oktenli, C.; Musabak, U.; Bozkurt, A.; Cansever, A.; Uzun, O.; Sanisoglu, S.Y.; Yesilova, Z.; Ozmenler, N.; Ozsahin, A.; Sengul, A. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin. Dev. Immunol., 2007, 76396, doi: 10.1155/2007/76396.
116. Myint, A.M.; Leonard, B.E.; Steinbusch, H.W.; Kim, Y.K. Th1, Th2, and Th3 cytokine alterations in major depression. J. Affect. Disord., 2005, 88(2), 167-173.
117. Lee, K.M.; Kim, Y.K. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive Disorder. Int. Immunopharmacol., 2006, 6(8), 1298-1304.
118. Kessing, L.V.; Søndergård, L.; Forman, J.L.; Andersen, P.K. Antidepressants and dementia. J. Affect. Disord., 2009, 117(1-2), 24-29.
119. Enache, D.; Winblad, B.; Aarsland, D. Depression in dementia: epidemiology, mechanisms, and treatment. Curr. Opin. Psychiatry, 2011, 24(6), 461-472.
120. Banerjee, S.; Hellier, J.; Dewey, M.; Romeo, R.; Ballard, C.; Baldwin, R.; Bentham, P.; Fox, C.; Holmes, C.; Katona, C.; Knapp, M.; Lawton, C.; Lindesay, J.; Livingston, G.; McCrae, N.; Moniz-Cook, E.; Murray, J.; Nurock, S.; Orrell, M.; O'Brien, J.; Poppe, M.; Thomas, A.; Walwyn, R.; Wilson, K.; Burns, A. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet, 2011, 378(9789), 403-411.